Biosenic SA

BioSenic signs a new subscription agreement for a maximum of EUR 1.2M in convertible bonds

08 янв 2024 12:00:00 Источник Nasdaq GlobeNewswire

ERRATUM: BioSenic on its way to find the necessary funds to perform its key clinical trial on chronic Graft-versus-Host Disease

08 дек 2023 01:00:00 Источник Nasdaq GlobeNewswire

BioSenic on its way to find the necessary funds to perform its key clinical trial on chronic Graft-versus-Host Disease

06 дек 2023 01:00:00 Источник Nasdaq GlobeNewswire

BioSenic provides third quarter 2023 Business Update

25 окт 2023 01:00:00 Источник Nasdaq GlobeNewswire

BioSenic to draw the final tranches of its present Global Tech Opportunities 15 convertible bonds program and secure runway end of January 2024

18 окт 2023 01:00:00 Источник Nasdaq GlobeNewswire

Correction: BioSenic S.A. : Transparency notifications received from François Rieger, Véronique Pomi, FA Dièse 3 SAS and Capital Grand Est SAS

17 окт 2023 01:00:00 Источник Nasdaq GlobeNewswire

BioSenic performs further analysis of its phase 2 clinical trial data, leading to an optimal administration scheme for its next late-stage trial of arsenic trioxide in cGvHD

27 сен 2023 01:00:00 Источник Nasdaq GlobeNewswire

BioSenic publishes new evidence of beneficial effects of arsenic trioxide treatment supporting clinical trial for systemic sclerosis

19 сен 2023 01:00:00 Источник Nasdaq GlobeNewswire

BioSenic reaches agreement on binding term sheets with main creditors to restructure past financial debts

14 сен 2023 01:00:00 Источник Nasdaq GlobeNewswire

BioSenic reports half year 2023 results

07 сен 2023 01:00:00 Источник Nasdaq GlobeNewswire

BioSenic S.A. : Information on the total number of voting rights and shares

01 сен 2023 01:00:00 Источник Nasdaq GlobeNewswire

BioSenic receives a Chinese patent with broad claims, protecting the combined use of metal ions and arsenic salts to treat a wide range of serious diseases

24 авг 2023 01:00:00 Источник Nasdaq GlobeNewswire

BioSenic S.A. : Information on the total number of voting rights and shares

03 авг 2023 01:00:00 Источник Nasdaq GlobeNewswire

BioSenic provides further update on negotiations with its main creditors

10 июл 2023 01:00:00 Источник Nasdaq GlobeNewswire

BioSenic S.A. : Information on the total number of voting rights and shares

03 июл 2023 01:00:00 Источник Nasdaq GlobeNewswire

BioSenic provides financial update

30 июн 2023 01:00:00 Источник Nasdaq GlobeNewswire

BioSenic presents data on its new copper-arsenic trioxide combination for immunological disorders at the 25th International Conference on Redox Medicine

20 июн 2023 05:31:14 Источник Nasdaq GlobeNewswire

BioSenic puts Phase IIb ALLOB trial on hold

19 июн 2023 01:00:00 Источник Nasdaq GlobeNewswire

BioSenic SA : Information on the total number of voting rights and shares

01 июн 2023 01:00:00 Источник Nasdaq GlobeNewswire

BioSenic provides update regarding current license agreement with Phebra

29 май 2023 01:00:00 Источник Nasdaq GlobeNewswire